LIFECORE BIOMEDICAL, INC. Restructuring and Related Cost, Cost Incurred to Date
LIFECORE BIOMEDICAL, INC. (LFCR) had Restructuring and Related Cost, Cost Incurred to Date of $18.49 million as of 2025-02-23, per its 10-Q filed 2025-04-03.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2025-04-03
- 2025-02-23: Restructuring and Related Cost, Cost Incurred to Date $18.49M.
- 2024-11-24: Restructuring and Related Cost, Cost Incurred to Date $32.50M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2025-02-23 | $18.49M 10-Q · filed 2025-04-03 |
| 2024-11-24 | $32.50M 10-Q · filed 2025-01-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |